Evaluation of tamoxifen as a therapy to augment alpha-1-antitrypsin concentrations in Z homozygous alpha-1-antitrypsin-deficient subjects. Academic Article uri icon

Overview

MeSH

  • Adult
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • alpha 1-Antitrypsin

MeSH Major

  • Homozygote
  • Tamoxifen
  • alpha 1-Antitrypsin Deficiency

abstract

  • Tamoxifen, an agent that binds to intracytoplasmic estrogen receptors, was evaluated as a possible means of increasing alpha-1-antitrypsin (alpha 1AT) synthesis and/or secretion and thus alpha 1AT serum levels in subjects with the homozygous form of alpha 1AT deficiency. Administration of tamoxifen (10 mg twice daily) to 30 Z homozygotes for a 30-day period was not associated with adverse reactions. However, although serum alpha 1AT levels increased significantly (p less than 0.03), the increase was minor (average pretreatment levels, 32 +/- 1 mg/dl; levels at 30 days of therapy, 35 +/- 1 mg/dl) and far below the "threshold" level of 80 mg/dl considered "protective" against an increased risk for emphysema. Thus, while the concept that increasing alpha 1AT synthesis and/or secretion is a rational goal for treating the Z homozygous form of alpha 1AT deficiency, tamoxifen will not be useful in this regard.

publication date

  • February 1987

has subject area

  • Adult
  • Drug Evaluation
  • Female
  • Homozygote
  • Humans
  • Male
  • Middle Aged
  • Tamoxifen
  • alpha 1-Antitrypsin
  • alpha 1-Antitrypsin Deficiency

Research

keywords

  • Journal Article

Identity

Language

  • eng

PubMed ID

  • 3492949

Additional Document Info

start page

  • 401

end page

  • 402

volume

  • 135

number

  • 2